Francais | English | Espanõl

From Wikipedia, the free encyclopedia

<tr><td align="center" style="background-color: #FFFFFF;" colspan="2"> Image:AM251.png</td></tr><tr><td style="background-color: #FFFFFF; vertical-align: top; white-space: nowrap;">Chemical formula </td><td style="background-color: #FFFFFF;">C₂₂H₂₁N₄ICl₂O </td></tr><tr><td style="background-color: #FFFFFF; vertical-align: bottom; white-space: nowrap;">Molar mass</td>

<td style="background-color: #FFFFFF;">555.238 g mol⁻¹</td></tr><tr><td style="background-color: #FFFFFF; vertical-align: top; white-space: nowrap; width: 30%;">Systematic name</td> <td style="background-color: #FFFFFF;">1-(2,4-dichlorophenyl)-5-(4-iodophenyl]])-4-methyl-N-(1-piperidyl)pyrazole-3-carboxamide</td></tr><tr><td align="center" style="background-color: #ddeeff;" colspan="2">Complete data</td></tr></table></div>

AM251 is a CB1 cannabinoid receptor antagonist. AM251 is structurally very close to SR 141716A (rimonabant), which both are biarylpyrazole cannabinoid receptor antagonists. In AM251 the p-chloro group attached to the phenyl substituent at C-5 of the pyrazole ring is replaced with a p-iodo group. The resulting compound exhibits slightly better binding affinity for the CB1 receptor with a Ki value of 7.5 nM compound to SR 141716A, which has a Ki value of 11.5 nM. However AM251 is about two-fold more selective for the CB1 receptor when compared to SR 141716A.[1]

[edit] References

1. Lan, R., Liu, Q., Fan, P., et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42 769-776 (1999).